This showed that the FoxO1 inhibitor is highly toxic to CLL cells obtained during ibrutinib therapy, but there was no increase in apoptosis compared with pretherapy samples (Figure 6G). Here, FOXO1 is linked to B-cell chronic lymphocytic leukemia.